Kyverna Therapeutics, Inc.
A clinical-stage biotech company engineering patients' own immune cells to fight autoimmune diseases such as lupus. Kyverna's lead therapy, KYV-101, is a CAR T-cell treatment that reprograms a patient's T cells to seek out and quiet the rogue immune cells driving the disease. Founded in 2018 in the San Francisco Bay Area, the company takes its name from the Greek word for "govern" or "guide," reflecting its aim to steer the immune system back into balance.
Bought 253.1K
Granted 21.7K · Bought 133.3K
Bought 133.3K
Granted 21.7K
Bought 910.0K
Bought 450.0K
Bought 450.0K
Granted 70.9K
Granted 58.0K
Granted 30.0K
Granted 46.6K · Sold 24.0K
Granted 21.7K
Granted 21.7K
Granted 18.0K
Granted 16.6K
Granted 11.0K
Granted 11.0K
Granted 10.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Vida Ventures GP III, L.L.C. +3 co-filers10% owner · 3 transactions | — | 4.78Mas of Feb 2024 | — | 253.1K | — |
| Seidenberg Beth CDirector · 5 transactions | — | 4.68M | 21.7K | 133.3K | — |
| Westlake BioPartners Fund I, L.P. +3 co-filers10% owner · 1 transaction | — | 4.66M | — | 133.3K | — |
| Cohen Fred EDirector · 3 transactions | — | 4.55M | 21.7K | — | — |
| Harper Sean E +4 co-filers10% owner · 2 transactions | — | 4.52Mas of Feb 2024 | — | — | — |
| Gilead Sciences, Inc.10% owner · 2 transactions | — | 4.13Mas of Feb 2024 | — | 910.0K | — |
| Rubin Michael P. +2 co-filersFormer 10% Owner · 2 transactions | — | 3.26Mas of Feb 2024 | — | 450.0K | — |
| Bain Capital Life Sciences Fund III, L.P. +4 co-filers10% owner · 2 transactions | — | 3.16Mas of Feb 2024 | — | 450.0K | — |
| Shaw ChristiExecutive Chairperson, Director · 4 transactions | — | 66.7K | 70.9K | — | — |
| Biddle Warner WestonChief Executive Officer, Director · 1 transaction | — | 58.0K | 58.0K | — | — |
| Jones Ryan AlexanderChief Financial Officer · 3 transactions | — | 56.0Kas of Apr 2025 | 30.0K | — | — |
| Walker Karen MarieChief Technology Officer · 4 transactions | — | 22.6K | 46.6K | — | 24.0K |
| Aktar MertDirector · 2 transactions | — | 21.7K | 21.7K | — | — |
| Clark Ian TDirector · 2 transactions | — | 21.7K | 21.7K | — | — |
| Gehchan NajiSee Remarks · 1 transaction | — | 18.0K | 18.0K | — | — |
| Spiegelman Daniel KDirector · 1 transaction | — | 16.6Kas of May 2025 | 16.6K | — | — |
| Emany Sravan KumarDirector · 1 transaction | — | 11.0K | 11.0K | — | — |
| Miller Andrew CraigDirector · 1 transaction | — | 11.0K | 11.0K | — | — |
| Grasso MarcChief Financial Officer · 1 transaction | — | 10.0K | 10.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +2.31M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.